Source: Health Products Regulatory Authority (IE) Revision Year: 2023 Publisher: AbbVie Limited, Citywest Business Campus, Dublin 24, Ireland
Duodopa 20 mg/ml + 5 mg/ml intestinal gel.
| Pharmaceutical Form |
|---|
|
Intestinal gel. Off white to slightly yellow gel. |
1 ml contains 20 mg levodopa and 5 mg carbidopa monohydrate.
100 ml contain 2000 mg levodopa and 500 mg carbidopa monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Carbidopa is a peripheral aromatic amino acid decarboxylase inhibitor. It prevents metabolism of levodopa to dopamine in the peripheral circulation, ensuring that a higher proportion of the dose reaches the brain, where dopamine exerts its therapeutic effects. A lower dose of levodopa can be used when it is coadministered with carbidopa, reducing the incidence and severity of peripheral side effects. |
|
Levodopa is a precursor of dopamine, and is given as dopamine replacement therapy in Parkinson's disease. |
|
|
| List of Excipients |
|---|
|
Carmellose sodium |
Total amount of 100 ml in PVC bag inside a hard plastic cassette for protection, carton with 7 cassettes.
AbbVie Limited, Citywest Business Campus, Dublin 24, Ireland
PA1824/002/001
Date of first authorisation: 18 November 2005
Date of last renewal: 21 January 2009
| Drug | Countries | |
|---|---|---|
| DUODOPA | Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.